September 4th 2024
YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
Researchers report positive preliminary experience with super pulse thulium fiber laser lithotripsy
March 11th 2021North American urologists analyzing outcomes from their initial experience treating urolithiasis with the high-power super pulse thulium fiber laser (Soltive) are encouraged by the results.
Observational study results put minimally invasive PCNL in a favorable light
January 26th 2021Analyses of data collected in a prospectively maintained database support the recommendation for urologists to consider the minimally invasive version of mini-percutaneous nephrolithotomy for stone removal in patients with medium-sized stones (10-20 mm).
SuperPulsed thulium fiber laser shows several advantages
April 13th 2020U.S. academic centers using the Soltive SuperPulsed Laser System to treat stones are finding it offers several advantages compared with holmium:YAG laser lithotripsy. But more research comparing the two is needed, according to a presentation at the 2019 World Congress of Endourology in Abu Dhabi, United Arab Emirates.
Pharmacotherapy reduces recurrence risk for aggressive stone disease
February 28th 2020Pharmacotherapy for reducing risk of stone recurrence is best reserved for patients with more aggressive disease who are at higher risk for another stone-related event, said Brett A. Johnson, MD, at the 2019 World Congress of Endourology and SWL in Abu Dhabi.
Protocol cuts opioid prescribing in stone patients
November 26th 2019Researchers in Tennessee are finding success with the use of an Enhanced Recovery After Surgery pathway that provides standardization for the anesthetic care and postoperative management of patients undergoing ureteroscopy and stent placement with a novel approach that minimizes opioid exposure.